Abionyx Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   32 Diseases   2 Products   2 Trials   93 News 
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    A Recombinant BIO-HDL (CER-001) Can Prevent SARS-COV2-Induced Renal Dysfunction by Restoring SR-BI Signalling (Mini-Orals Hall) -  May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_1107;    
    Consistent with in vitro results, analysis of renal biopsies from COVID-19 patients with proteinuria showed increased SR-BI and ACE-2 cytoplasmic signals and reduced expression at the apical domain of injured tubules. CONCLUSION Our data confirmed the key role of lipid profile in SARS-COV2 infection, evaluating the molecular signalling involved in HDL metabolism and inflammatory processes, and could offer new therapeutic strategies for COVID-19 patients.
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Clinical, Journal:  No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. (Pubmed Central) -  Jun 24, 2021   
    CONCLUSION Our data confirmed the key role of lipid profile in SARS-COV2 infection, evaluating the molecular signalling involved in HDL metabolism and inflammatory processes, and could offer new therapeutic strategies for COVID-19 patients. In patients with genetically determined very low HDL-cholesterol, 24 weeks of treatment with HDL mimetic CER-001 did not reduce carotid vessel wall dimensions or arterial wall inflammation, compared with placebo.
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Trial completion date, Trial termination, Trial primary completion date:  TANGO: CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (clinicaltrials.gov) -  Feb 11, 2019   
    P3,  N=30, Terminated, 
    Reverse cholesterol transport remains a challenging therapeutic pathway to be explored. Trial completion date: Dec 2017 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Oct 2018; Lack of efficacy
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Trial completion:  CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) -  Jan 31, 2017   
    P2,  N=301, Completed, 
    Trial completion date: Dec 2017 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Oct 2018; Lack of efficacy Active, not recruiting --> Completed
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Enrollment closed:  CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) -  Sep 2, 2016   
    P2,  N=301, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Enrollment open:  CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) -  Aug 5, 2015   
    P2,  N=292, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    New P2 trial:  CARAT: CER-001 Atherosclerosis Regression ACS Trial (clinicaltrials.gov) -  Jun 29, 2015   
    P2,  N=292, Not yet recruiting, 
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Enrollment change:  Exploratory Study of Plaque Regression (clinicaltrials.gov) -  Jul 29, 2013   
    P2,  N=10, Completed, 
    Active, not recruiting --> Completed N=15 --> 10
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    Trial completion:  Exploratory Study of Plaque Regression (clinicaltrials.gov) -  Jul 29, 2013   
    P2,  N=10, Completed, 
    N=15 --> 10 Active, not recruiting --> Completed
  • ||||||||||  human recombinant apoA-I/sphingomyelin/dipalmitoylphosphatidylglycerol (CER-001) / Abionyx Pharma
    New P2 trial:  Exploratory Study of Plaque Regression (clinicaltrials.gov) -  Jan 22, 2012   
    P2,  N=10, Completed,